| Year |
Citation |
Score |
| 2024 |
Fatima N, Shen Y, Crassini K, Burling O, Thurgood L, Iwanowicz EJ, Lang H, Karanewsky DS, Christopherson RI, Mulligan SP, Best OG. The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells . Leukemia & Lymphoma. 1-13. PMID 38227293 DOI: 10.1080/10428194.2023.2300055 |
0.807 |
|
| 2023 |
Fatima N, Best OG, Belov L, Christopherson RI. The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells. Leukemia & Lymphoma. 1-8. PMID 37933638 DOI: 10.1080/10428194.2023.2275530 |
0.327 |
|
| 2021 |
Shen Y, Coyle L, Kerridge I, Stevenson W, Arthur C, McKinlay N, Fay K, Ward C, Greenwood M, Best OG, Solterbeck A, Guminski A, Shumack S, Mulligan SP. Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. Ejhaem. 3: 129-138. PMID 35846218 DOI: 10.1002/jha2.366 |
0.71 |
|
| 2021 |
Fatima N, Shen Y, Crassini K, Iwanowicz EJ, Lang H, Karanewsky DS, Christopherson RI, Mulligan SP, Best OG. The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. Ejhaem. 2: 81-93. PMID 35846080 DOI: 10.1002/jha2.160 |
0.832 |
|
| 2021 |
Thurgood LA, Best OG, Rowland A, Lower KM, Brooks DA, Kuss BJ. Lipid uptake in chronic lymphocytic leukemia. Experimental Hematology. PMID 34896245 DOI: 10.1016/j.exphem.2021.12.193 |
0.324 |
|
| 2021 |
Almazi JG, Alomari M, Belov L, Best OG, Shen Y, Graham ME, Mulligan SP, Christopherson RI. Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines. Nucleosides, Nucleotides & Nucleic Acids. 1-7. PMID 34886743 DOI: 10.1080/15257770.2021.2013500 |
0.625 |
|
| 2021 |
Do C, Best OG, Thurgood L, Hotinski A, Apostolou S, Mulligan SP, Lower K, Kuss B. Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial. British Journal of Haematology. 193: 556-560. PMID 33851417 DOI: 10.1111/bjh.17394 |
0.562 |
|
| 2020 |
Fatima N, Crassini KR, Thurgood L, Shen Y, Christopherson RI, Kuss B, Mulligan SP, Best OG. Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia. Cancer Drug Resistance (Alhambra, Calif.). 3: 532-549. PMID 35582439 DOI: 10.20517/cdr.2019.111 |
0.793 |
|
| 2020 |
Shen Y, Crassini K, Fatima N, O'Dwyer M, O'Neill M, Christopherson RI, Mulligan SP, Best OG. IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. Blood Advances. 4: 5093-5106. PMID 33085757 DOI: 10.1182/bloodadvances.2019001369 |
0.826 |
|
| 2020 |
Gifford GK, Gifford AJ, Chen Q, Shen Y, Gabrielli S, Gill AJ, Stevenson WS, Best OG. Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma. Leukemia & Lymphoma. 1-13. PMID 32249639 DOI: 10.1080/10428194.2020.1742899 |
0.475 |
|
| 2019 |
Crassini K, Stevenson WS, Mulligan SP, Best OG. Molecular pathogenesis of chronic lymphocytic leukaemia. British Journal of Haematology. PMID 31364161 DOI: 10.1111/Bjh.16102 |
0.791 |
|
| 2019 |
Shen Y, Crassini K, Sandhu S, Fatima N, Christopherson RI, Mulligan SP, Best OG. Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. Leukemia & Lymphoma. 1-12. PMID 30648436 DOI: 10.1080/10428194.2018.1542148 |
0.83 |
|
| 2019 |
Shen Y, Crassini KR, Fatima N, Christopherson R, Mulligan SP, Best OG. Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment Blood. 134: 5443-5443. DOI: 10.1182/Blood-2019-130082 |
0.827 |
|
| 2018 |
Crassini K, Shen Y, O'Dwyer M, O'Neill M, Christopherson R, Mulligan S, Best OG. The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. British Journal of Haematology. PMID 29978459 DOI: 10.1111/Bjh.15447 |
0.831 |
|
| 2018 |
Crassini KR, Best OG, Mulligan SP. Immune failure, infection and survival in chronic lymphocytic leukemia. Haematologica. 103: e329. PMID 29970494 DOI: 10.3324/Haematol.2018.196543 |
0.764 |
|
| 2018 |
Crassini K, Pyke T, Shen Y, Stevenson WS, Christopherson RI, Mulligan SP, Best OG. Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells. Leukemia & Lymphoma. 1-12. PMID 29911936 DOI: 10.1080/10428194.2018.1455974 |
0.831 |
|
| 2018 |
Crassini K, Shen Y, Stevenson WS, Christopherson R, Ward C, Mulligan SP, Best OG. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. British Journal of Haematology. PMID 29767411 DOI: 10.1111/Bjh.15282 |
0.829 |
|
| 2018 |
Crassini KR, Zhang E, Balendran S, Freeman JA, Best OG, Forsyth CJ, Mackinlay NJ, Han P, Stevenson WS, Mulligan SP. Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. British Journal of Haematology. PMID 29468645 DOI: 10.1111/Bjh.15146 |
0.776 |
|
| 2018 |
Crassini KR, Shen Y, Stevenson WS, Mulligan SP, Best OG, Christopherson R. mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node Blood. 132: 1850-1850. DOI: 10.1182/Blood-2018-99-118264 |
0.787 |
|
| 2018 |
Mulligan SP, Freeman JA, Badoux X, Eek R, Cull G, Mackinlay NJ, Murphy NE, Carradice DP, Solterbeck AC, Best OG, Tam CS, Kuss BJ. Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy Blood. 132: 3144-3144. DOI: 10.1182/Blood-2018-99-116287 |
0.528 |
|
| 2018 |
Shen Y, Crassini KR, O'Dwyer ME, O'Neill MF, Christopherson R, Mulligan SP, Best OG. The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53-Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment Blood. 132: 1870-1870. DOI: 10.1182/Blood-2018-99-115574 |
0.826 |
|
| 2018 |
Rizwan N, Shen Y, Iwanowicz E, Mulligan SP, Crassini KR, Christopherson R, Best OG. ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment Blood. 132: 3145-3145. DOI: 10.1182/Blood-2018-99-115555 |
0.823 |
|
| 2018 |
Bai L, Best OG, Xia W, Peters L, Wong K, Ward C, Greenwood M. DNA Damage in Haemopoeitic Stem Cells Impacts on Neutrophil and Platelet Engraftment Following Autologous Transplantation Blood. 132: 4622-4622. DOI: 10.1182/Blood-2018-99-115530 |
0.413 |
|
| 2018 |
Mulligan SP, Gill D, Cull G, Berkahn L, Simpson D, Campbell P, Harrup RA, Mackinlay NJ, Tam CS, Badoux X, Best OG, Kuss BJ. Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status Blood. 132: 4432-4432. DOI: 10.1182/Blood-2018-99-114064 |
0.525 |
|
| 2017 |
Shen Y, Best OG, Mulligan SP, Christopherson RI. Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment. Leukemia & Lymphoma. 1-11. PMID 29164976 DOI: 10.1080/10428194.2017.1403598 |
0.593 |
|
| 2017 |
Belov L, Hallal S, Matic K, Zhou J, Wissmueller S, Ahmed N, Tanjil S, Mulligan SP, Best OG, Simpson RJ, Christopherson RI. Surface Profiling of Extracellular Vesicles from Plasma or Ascites Fluid Using DotScan Antibody Microarrays. Methods in Molecular Biology (Clifton, N.J.). 1619: 263-301. PMID 28674892 DOI: 10.1007/978-1-4939-7057-5_20 |
0.621 |
|
| 2016 |
Li J, Best OG, Mulligan SP, Fernando SL. Exploring the mechanisms of large local reactions to insect bites in patients with chronic lymphocytic leukaemia. Pathology. 48: S43. PMID 27773034 DOI: 10.1016/J.Pathol.2015.12.105 |
0.528 |
|
| 2016 |
Li J, Best OG, Mulligan SP, Fernando SL. Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors. Leukemia & Lymphoma. 1-4. PMID 27104626 DOI: 10.3109/10428194.2016.1173208 |
0.551 |
|
| 2016 |
Belov L, Matic KJ, Hallal S, Best OG, Mulligan SP, Christopherson RI. Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. Journal of Extracellular Vesicles. 5: 25355. PMID 27086589 DOI: 10.3402/Jev.V5.25355 |
0.586 |
|
| 2015 |
Kaufman K, Jenkins Y, Alomari M, Mirzaei M, Best O, Pascovici D, Mactier S, Mulligan S, Haynes P, Christopherson RI. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Oncotarget. PMID 26556860 DOI: 10.18632/Oncotarget.5715 |
0.652 |
|
| 2015 |
Huang PY, Mactier S, Armacki N, Best OG, Belov L, Kaufman KL, Pascovici D, Mulligan SP, Christopherson RI. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma. 1-29. PMID 26422656 DOI: 10.3109/10428194.2015.1094692 |
0.632 |
|
| 2015 |
Crassini K, Mulligan SP, Best OG. Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date. World Journal of Clinical Cases. 3: 694-704. PMID 26301230 DOI: 10.12998/Wjcc.V3.I8.694 |
0.823 |
|
| 2015 |
Crassini K, Stevenson WS, Mulligan SP, Best OG. The MEK1/2 inhibitor, MEKi-1, induces cell death in Chronic Lymphocytic Leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. Leukemia & Lymphoma. 1-29. PMID 25804768 DOI: 10.3109/10428194.2015.1032963 |
0.822 |
|
| 2015 |
Hamad N, Kliman D, Best OG, Caramins M, Hertzberg M, Lindeman R, Porter R, Mulligan SP. Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management. British Journal of Haematology. 168: 350-60. PMID 25256787 DOI: 10.1111/Bjh.13134 |
0.562 |
|
| 2014 |
Christopherson RI, Mactier S, Almazi JG, Kohnke PL, Best OG, Mulligan SP. Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells. Nucleosides, Nucleotides & Nucleic Acids. 33: 375-83. PMID 24940695 DOI: 10.1080/15257770.2013.863334 |
0.698 |
|
| 2014 |
Huang PY, Best OG, Almazi JG, Belov L, Davis ZA, Majid A, Dyer MJ, Pascovici D, Mulligan SP, Christopherson RI. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma. 55: 2085-92. PMID 24289109 DOI: 10.3109/10428194.2013.867486 |
0.506 |
|
| 2014 |
Stevenson WS, Best OG, Przybylla A, Chen Q, Singh N, Koleth M, Pierce S, Kennedy T, Tong W, Kuang SQ, Garcia-Manero G. DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia. Leukemia. 28: 787-93. PMID 24045499 DOI: 10.1038/leu.2013.270 |
0.467 |
|
| 2014 |
Best OG, Crassini K, O'Neill M, O'Dwyer ME, Mulligan SP. Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia Blood. 124: 4693-4693. DOI: 10.1182/Blood.V124.21.4693.4693 |
0.818 |
|
| 2014 |
Crassini K, Stevenson WS, Mulligan SP, Best OG. MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling Blood. 124: 3330-3330. DOI: 10.1182/Blood.V124.21.3330.3330 |
0.827 |
|
| 2014 |
Best OG, Pyke T, Crassini K, Stevenson WS, Mulligan SP. The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment Blood. 124: 3326-3326. DOI: 10.1182/Blood.V124.21.3326.3326 |
0.828 |
|
| 2013 |
Huang PY, Kohnke P, Belov L, Best OG, Mulligan SP, Christopherson RI. Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society For Pharmaceutical Sciences, Sociã©Tã© Canadienne Des Sciences Pharmaceutiques. 16: 231-7. PMID 23958192 DOI: 10.18433/J3F01C |
0.57 |
|
| 2013 |
Best OG, Crassini K, Freeman JA, Mulligan SP. The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). Scandinavian Journal of Infectious Diseases. 45: 729. PMID 23826794 DOI: 10.3109/00365548.2013.809477 |
0.763 |
|
| 2013 |
Best OG, Tam C. Protein kinase C isoform expression in chronic lymphocytic leukemia: A potential target for therapy? Leukemia and Lymphoma. 54: 2098-2099. PMID 23469961 DOI: 10.3109/10428194.2013.779692 |
0.416 |
|
| 2013 |
Che Y, Best OG, Zhong L, Kaufman KL, Mactier S, Raftery M, Graves LM, Mulligan SP, Christopherson RI. Hsp90 Inhibitor SNX-7081 dysregulates proteins involved with DNA repair and replication and the cell cycle in human chronic lymphocytic leukemia (CLL) cells. Journal of Proteome Research. 12: 1710-22. PMID 23458665 DOI: 10.1021/Pr301055Y |
0.657 |
|
| 2013 |
Best OG, Mulligan SP. The phosphoinositide 3-kinase pathway in chronic lymphocytic leukemia: evidence for phosphatase and tensin homolog deletion on chromosome 10 deregulation. Leukemia & Lymphoma. 54: 1123-4. PMID 23134359 DOI: 10.3109/10428194.2012.746685 |
0.618 |
|
| 2013 |
Freeman JA, Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, Han P, Stevenson W, Mulligan SP. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leukemia & Lymphoma. 54: 99-104. PMID 22738394 DOI: 10.3109/10428194.2012.706285 |
0.761 |
|
| 2012 |
Best OG, Mulligan SP. Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. Leukemia & Lymphoma. 53: 2314-20. PMID 22646928 DOI: 10.3109/10428194.2012.698278 |
0.69 |
|
| 2012 |
Almazi JG, Mactier S, Best OG, Crossett B, Mulligan SP, Christopherson RI. Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics. Clinical Applications. 6: 279-90. PMID 22641291 DOI: 10.1002/Prca.201200003 |
0.593 |
|
| 2012 |
Best OG, Che Y, Singh N, Forsyth C, Christopherson RI, Mulligan SP. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia & Lymphoma. 53: 1367-75. PMID 22149137 DOI: 10.3109/10428194.2011.647310 |
0.699 |
|
| 2012 |
Huang PY, Best OG, Belov L, Mulligan SP, Christopherson RI. Surface profiles for subclassification of chronic lymphocytic leukemia. Leukemia & Lymphoma. 53: 1046-56. PMID 22023531 DOI: 10.3109/10428194.2011.631370 |
0.61 |
|
| 2012 |
Mazi JGA, Best OG, Alomari M, Crossett B, Mulligan SP, Christopherson RI. Fludarabine induced changes in p63 and p73 expression and p53 protein binding partners F1000research. 3. DOI: 10.7490/F1000Research.1089937.1 |
0.545 |
|
| 2011 |
Huang PY, Best OG, Mactier S, Majid A, Dyer M, Mulligan SP, Christopherson RI. 4.7 Identification of Novel Protein Markers of Progressive Chronic Lymphocytic Leukaemia Clinical Lymphoma Myeloma and Leukemia. 11: S221-S222. DOI: 10.1016/J.Clml.2011.09.127 |
0.609 |
|
| 2011 |
Al-Mazi JG, Best OG, Alomari M, Mulligan SP, Christopherson RI. 2.19 Fludarabine-Induced Changes in p63 and p73 Expression and TP53 Protein Binding in TP53 Wild-Type and Mutated Cell Lines Clinical Lymphoma Myeloma and Leukemia. 11: S171. DOI: 10.1016/J.Clml.2011.09.052 |
0.584 |
|
| 2010 |
Best OG, Singh N, Forsyth C, Mulligan SP. The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway. British Journal of Haematology. 151: 185-8. PMID 20738310 DOI: 10.1111/J.1365-2141.2010.08348.X |
0.679 |
|
| 2010 |
Mulligan SP, Gill DS, Renwick WEP, Sulda ML, Best OG, Kuss BJ, Seymour JF. The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Blood. 116: 699-699. DOI: 10.1182/Blood.V116.21.699.699 |
0.573 |
|
| 2010 |
Best OG, Mulligan SP. The Hsp90 Inhibitor SNX7081 Restores the Fludarabine Sensitivity of Chronic Lymphocytic Leukemia (CLL) Cells Harbouring Mutations of ATM or TP53 Blood. 116: 2473-2473. DOI: 10.1182/Blood.V116.21.2473.2473 |
0.688 |
|
| 2009 |
Mulligan CS, Best OG, Mulligan SP. The precursor of chronic lymphocytic leukemia. The New England Journal of Medicine. 360: 2575; author reply 2. PMID 19516039 DOI: 10.1056/NEJMc090559 |
0.572 |
|
| Show low-probability matches. |